Literature DB >> 24963129

Optimum lean body formulation for correction of standardized uptake value in PET imaging.

Abdel K Tahari1, David Chien2, Javad R Azadi2, Richard L Wahl2.   

Abstract

UNLABELLED: Standardized uptake value (SUV) normalized by lean body mass ([LBM] SUL) is becoming a popular metric for quantitative assessment of clinical PET. Sex-specific quantitative effects of different LBM formulations on liver SUV have not been well studied.
METHODS: (18)F-FDG PET/CT scans from 1,033 consecutive adult (501 women, 532 men) studies were reviewed. Liver SUV was measured with a 3-cm-diameter spheric region of interest in the right hepatic lobe and corrected for LBM using the sex-specific James and Janmahasatian formulations.
RESULTS: Body weight was 71.0 ± 20.7 kg (range, 18.0-175.0 kg) and 82.9 ± 18.6 kg (range, 23.0-159.0 kg) for women and men, respectively. SUV, based on body weight, has a significantly positive correlation with weight for both women (r = 0.58, P < 0.0001) and men (r = 0.54, P < 0.0001). This correlation is reduced in men (r = 0.11, P = 0.01) and becomes negative for women (r = -0.35, P = 0.0001) with the James formulation of SUL. This negative correlation was eliminated when the very obese women (body mass index ≥ 35) were excluded from the analysis (r = 0.13, P = 0.8). The Janmahasatian formulation annuls the correlation between SUL and weight for women (r = 0.04, P = 0.4) and decreases it for men (r = 0.13, P = 0.003).
CONCLUSION: Hepatic correction with the more common James formulation for body lean mass breaks down and shows low SUL values in very obese patients. The adoption of the Janmahasatian formula for estimation of LBM in modern PET scanners and display workstations is recommended, in view of the increasing frequency of obesity.
© 2014 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

Entities:  

Keywords:  FDG; LBM; PET; SUL; SUV; gender-specific

Mesh:

Year:  2014        PMID: 24963129      PMCID: PMC4337860          DOI: 10.2967/jnumed.113.136986

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  11 in total

1.  Reevaluation of the standardized uptake value for FDG: variations with body weight and methods for correction.

Authors:  Y Sugawara; K R Zasadny; A W Neuhoff; R L Wahl
Journal:  Radiology       Date:  1999-11       Impact factor: 11.105

2.  Predictive performance of the 'Minto' remifentanil pharmacokinetic parameter set in morbidly obese patients ensuing from a new method for calculating lean body mass.

Authors:  Luca La Colla; Andrea Albertin; Giorgio La Colla; Andrea Porta; Giorgio Aldegheri; Domenico Di Candia; Fausto Gigli
Journal:  Clin Pharmacokinet       Date:  2010       Impact factor: 6.447

3.  Pharmacokinetic model-driven remifentanil administration in the morbidly obese: the 'critical weight' and the 'fictitious height', a possible solution to an unsolved problem?

Authors:  L La Colla; A Albertin; G La Colla
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 4.  Use of PET for monitoring cancer therapy and for predicting outcome.

Authors:  Wolfgang A Weber
Journal:  J Nucl Med       Date:  2005-06       Impact factor: 10.057

5.  Recommendations on the use of 18F-FDG PET in oncology.

Authors:  James W Fletcher; Benjamin Djulbegovic; Heloisa P Soares; Barry A Siegel; Val J Lowe; Gary H Lyman; R Edward Coleman; Richard Wahl; John Christopher Paschold; Norbert Avril; Lawrence H Einhorn; W Warren Suh; David Samson; Dominique Delbeke; Mark Gorman; Anthony F Shields
Journal:  J Nucl Med       Date:  2008-02-20       Impact factor: 10.057

6.  Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction.

Authors:  K R Zasadny; R L Wahl
Journal:  Radiology       Date:  1993-12       Impact factor: 11.105

7.  Within-patient variability of (18)F-FDG: standardized uptake values in normal tissues.

Authors:  Nancy Paquet; Adelin Albert; Jacqueline Foidart; Roland Hustinx
Journal:  J Nucl Med       Date:  2004-05       Impact factor: 10.057

Review 8.  From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors.

Authors:  Richard L Wahl; Heather Jacene; Yvette Kasamon; Martin A Lodge
Journal:  J Nucl Med       Date:  2009-05       Impact factor: 10.057

9.  A fluorinated glucose analog, 2-fluoro-2-deoxy-D-glucose (F-18): nontoxic tracer for rapid tumor detection.

Authors:  P Som; H L Atkins; D Bandoypadhyay; J S Fowler; R R MacGregor; K Matsui; Z H Oster; D F Sacker; C Y Shiue; H Turner; C N Wan; A P Wolf; S V Zabinski
Journal:  J Nucl Med       Date:  1980-07       Impact factor: 10.057

10.  The role of PET in monitoring therapy.

Authors:  Rodney J Hicks
Journal:  Cancer Imaging       Date:  2005-06-21       Impact factor: 3.909

View more
  35 in total

1.  Usefulness of standardized uptake value normalized by individual CT-based lean body mass in application of PET response criteria in solid tumors (PERCIST).

Authors:  Atsushi Narita; Susumu Shiomi; Yutaka Katayama; Takashi Yamanaga; Hiromitsu Daisaki; Kazuo Hamada; Yasuyoshi Watanabe
Journal:  Radiol Phys Technol       Date:  2016-02-12

2.  Repeatability of 18F-FDG PET/CT in Advanced Non-Small Cell Lung Cancer: Prospective Assessment in 2 Multicenter Trials.

Authors:  Wolfgang A Weber; Constantine A Gatsonis; P David Mozley; Lucy G Hanna; Anthony F Shields; Denise R Aberle; Ramaswamy Govindan; Drew A Torigian; Joel S Karp; Jian Q Michael Yu; Rathan M Subramaniam; Robert A Halvorsen; Barry A Siegel
Journal:  J Nucl Med       Date:  2015-04-23       Impact factor: 10.057

3.  Quantitative assessment of metabolic tumor burden in molecular subtypes of primary breast cancer with FDG PET/CT.

Authors:  Wei Chen; Lei Zhu; Xiaozhou Yu; Qiang Fu; Wengui Xu; Ping Wang
Journal:  Diagn Interv Radiol       Date:  2018-11       Impact factor: 2.630

4.  18F-DOPA uptake parameters in glioma: effects of patients' characteristics and prior treatment history.

Authors:  Luciano Carideo; Giuseppe Minniti; Marcelo Mamede; Claudia Scaringi; Ivana Russo; Francesco Scopinaro; Francesco Cicone
Journal:  Br J Radiol       Date:  2018-01-19       Impact factor: 3.039

Review 5.  Practical PERCIST: A Simplified Guide to PET Response Criteria in Solid Tumors 1.0.

Authors:  Joo Hyun O; Martin A Lodge; Richard L Wahl
Journal:  Radiology       Date:  2016-02-24       Impact factor: 11.105

6.  Recurrent bladder carcinoma: clinical and prognostic role of 18 F-FDG PET/CT.

Authors:  Pierpaolo Alongi; Federico Caobelli; Roberta Gentile; Alessandro Stefano; Giorgio Russo; Domenico Albano; Sergio Baldari; Maria Carla Gilardi; Massimo Midiri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-08-26       Impact factor: 9.236

7.  Population pharmacokinetics and analgesic potency of oxycodone.

Authors:  Byung-Moon Choi; Yong-Hun Lee; Sang-Mee An; Soo-Han Lee; Eun-Kyung Lee; Gyu-Jeong Noh
Journal:  Br J Clin Pharmacol       Date:  2016-09-29       Impact factor: 4.335

8.  PERCIST in Perspective.

Authors:  Joo Hyun O; Richard L Wahl
Journal:  Nucl Med Mol Imaging       Date:  2017-12-18

Review 9.  Brown Adipose Reporting Criteria in Imaging STudies (BARCIST 1.0): Recommendations for Standardized FDG-PET/CT Experiments in Humans.

Authors:  Kong Y Chen; Aaron M Cypess; Maren R Laughlin; Carol R Haft; Houchun Harry Hu; Miriam A Bredella; Sven Enerbäck; Paul E Kinahan; Wouter van Marken Lichtenbelt; Frank I Lin; John J Sunderland; Kirsi A Virtanen; Richard L Wahl
Journal:  Cell Metab       Date:  2016-08-09       Impact factor: 27.287

10.  Quantitative body mass characterization before and after head and neck cancer radiotherapy: A challenge of height-weight formulae using computed tomography measurement.

Authors:  Sasikarn Chamchod; Clifton D Fuller; Abdallah S R Mohamed; Aaron Grossberg; Jay A Messer; Jolien Heukelom; G Brandon Gunn; Micheal E Kantor; Hillary Eichelberger; Adam S Garden; David I Rosenthal
Journal:  Oral Oncol       Date:  2016-08-31       Impact factor: 5.337

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.